BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29451304)

  • 1. Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.
    Liew PL; Huang RL; Weng YC; Fang CL; Hui-Ming Huang T; Lai HC
    Int J Cancer; 2018 Jul; 143(2):355-367. PubMed ID: 29451304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromosomal Instability and mTORC1 Activation through PTEN Loss Contribute to Proteotoxic Stress in Ovarian Carcinoma.
    Chui MH; Doodnauth SA; Erdmann N; Tiedemann RE; Sircoulomb F; Drapkin R; Shaw P; Rottapel R
    Cancer Res; 2019 Nov; 79(21):5536-5549. PubMed ID: 31530568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular origin and taxonomy of mucinous ovarian carcinoma.
    Cheasley D; Wakefield MJ; Ryland GL; Allan PE; Alsop K; Amarasinghe KC; Ananda S; Anglesio MS; Au-Yeung G; Böhm M; Bowtell DDL; Brand A; Chenevix-Trench G; Christie M; Chiew YE; Churchman M; DeFazio A; Demeo R; Dudley R; Fairweather N; Fedele CG; Fereday S; Fox SB; Gilks CB; Gourley C; Hacker NF; Hadley AM; Hendley J; Ho GY; Hughes S; Hunstman DG; Hunter SM; Jobling TW; Kalli KR; Kaufmann SH; Kennedy CJ; Köbel M; Le Page C; Li J; Lupat R; McNally OM; McAlpine JN; Mes-Masson AM; Mileshkin L; Provencher DM; Pyman J; Rahimi K; Rowley SM; Salazar C; Samimi G; Saunders H; Semple T; Sharma R; Sharpe AJ; Stephens AN; Thio N; Torres MC; Traficante N; Xing Z; Zethoven M; Antill YC; Scott CL; Campbell IG; Gorringe KL
    Nat Commun; 2019 Sep; 10(1):3935. PubMed ID: 31477716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance.
    Wamunyokoli FW; Bonome T; Lee JY; Feltmate CM; Welch WR; Radonovich M; Pise-Masison C; Brady J; Hao K; Berkowitz RS; Mok S; Birrer MJ
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):690-700. PubMed ID: 16467078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of multidrug resistance 1 expression by CDX2 in ovarian mucinous adenocarcinoma.
    Koh I; Hinoi T; Sentani K; Hirata E; Nosaka S; Niitsu H; Miguchi M; Adachi T; Yasui W; Ohdan H; Kudo Y
    Cancer Med; 2016 Jul; 5(7):1546-55. PubMed ID: 27060927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.
    Marquez RT; Baggerly KA; Patterson AP; Liu J; Broaddus R; Frumovitz M; Atkinson EN; Smith DI; Hartmann L; Fishman D; Berchuck A; Whitaker R; Gershenson DM; Mills GB; Bast RC; Lu KH
    Clin Cancer Res; 2005 Sep; 11(17):6116-26. PubMed ID: 16144910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methylation changes in epithelial ovarian cancer histotypes.
    Earp MA; Cunningham JM
    Genomics; 2015 Dec; 106(6):311-21. PubMed ID: 26363302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiling of mucinous epithelial ovarian cancer by weighted gene co-expression network analysis.
    Zhang GH; Chen MM; Kai JY; Ma Q; Zhong AL; Xie SH; Zheng H; Wang YC; Tong Y; Lu RQ; Guo L
    Gene; 2019 Aug; 709():56-64. PubMed ID: 31108164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of REG4 in ovarian mucinous tumors.
    Huang Q; Chen X; Lu W; Lai M; Lu B
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
    Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin.
    Werness BA; DiCioccio RA; Piver MS
    Hum Pathol; 1997 May; 28(5):626-30. PubMed ID: 9158713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
    Bazzaro M; Lee MK; Zoso A; Stirling WL; Santillan A; Shih IeM; Roden RB
    Cancer Res; 2006 Apr; 66(7):3754-63. PubMed ID: 16585202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucinous tumors of the ovary: current thoughts on diagnosis and management.
    Brown J; Frumovitz M
    Curr Oncol Rep; 2014 Jun; 16(6):389. PubMed ID: 24777667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.
    Lehtinen L; Vesterkvist P; Roering P; Korpela T; Hattara L; Kaipio K; Mpindi JP; Hynninen J; Auranen A; Davidson B; Haglund C; Iljin K; Grenman S; Siitari H; Carpen O
    PLoS One; 2016; 11(3):e0151590. PubMed ID: 26981633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and mutational analysis of c-kit in ovarian surface epithelial tumors.
    Kim DJ; Lee MH; Park TI; Bae HI
    J Korean Med Sci; 2006 Feb; 21(1):81-5. PubMed ID: 16479070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer.
    Abobaker S; Kulbe H; Taube ET; Darb-Esfahani S; Richter R; Denkert C; Jank P; Sehouli J; Braicu EI
    Anticancer Res; 2022 Apr; 42(4):1739-1747. PubMed ID: 35346992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.
    Obata K; Morland SJ; Watson RH; Hitchcock A; Chenevix-Trench G; Thomas EJ; Campbell IG
    Cancer Res; 1998 May; 58(10):2095-7. PubMed ID: 9605750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations.
    Hunter SM; Gorringe KL; Christie M; Rowley SM; Bowtell DD; ; Campbell IG
    Clin Cancer Res; 2012 Oct; 18(19):5267-77. PubMed ID: 22891197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interphase cytogenetic analysis of mucinous ovarian neoplasms.
    Diebold J; Siegert S; Baretton GB; Suchy B; Meier W; Haas CJ; Löhrs U
    Lab Invest; 1997 May; 76(5):661-70. PubMed ID: 9166285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with Proteasome Inhibition in Human Ovarian Cancer Cells.
    Liu Y; Peng X; Li H; Jiao W; Peng X; Shao J; Xu Y; Wang R; Wang W; Kong D
    Recent Pat Anticancer Drug Discov; 2021; 16(3):350-362. PubMed ID: 33655847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.